Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there ...
20hon MSN
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, ...
Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an ...
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...
The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company ... versus the mean estimate of ...
Eli Lilly has asked the U.S. government to pause price negotiations for prescription drugs, Bloomberg News reported on Monday ...
That, in addition to lower-than-expected channel inventory at year-end, contributed to our Q4 results,” said Eli Lilly Chair and CEO David A. Ricks. “We continued to make progress on our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback